Company Description
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body.
Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Mahesh Karande |
Contact Details
Address: 140 First Street, Suite 501 Cambridge, Massachusetts 02141 United States | |
| Phone | (617) 949-4360 |
| Website | omegatherapeutics.com |
Stock Details
| Ticker Symbol | OMGA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001850838 |
| CUSIP Number | 68217N105 |
| ISIN Number | US68217N1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mahesh Karande | President, Chief Executive Officer and Board Director |
| Ling Zeng Esq., J.D. | Chief Legal and Administrative Officer and Secretary |
| Dr. Yan Moore M.D. | Chief Medical Officer |
| Joshua Reed M.B.A. | Chief Financial Officer |
| Dr. Sivakesava Sakhamuri Ph.D. | Senior Vice President and Head of Technical Operations and Quality |
| Dr. Thomas McCauley Ph.D. | Chief Scientific Officer |
| Anthony Mullin | Chief People Officer |
| Charles O'Donnell Ph.D. | Vice President and Head of Computational Genomics and Data Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 16, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 5, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |